Healthy Skepticism Library item: 16749

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Wolfe SM.
Dangers of rosuvastatin identified before and after FDA approval.
Lancet 2004 Jun 26; 363:(9427):2189-90
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(04)16513-6

Keywords:
* Drug Approval* * Fluorobenzenes/adverse effects* * Humans * Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects* * Kidney Failure/chemically induced * Muscular Diseases/chemically induced * Pyrimidines/adverse effects* * Rhabdomyolysis/chemically induced * Sulfonamides/adverse effects* * United States * United States Food and Drug Administration

Please
Click to Register

(read more)

then
Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

Announcements

PharmedOut’s annual conference: Missing The Target: When Practitioners Harm More Than Heal

No Free Lunch is merging with Healthy Skepticism

Conference program: Pharma Knows Best? Managing Medical Knowledge

Prescrire’s proposals for France’s national conference on medicines policy

Pharmed Out Conference ‘Pharma Knows Best? Managing Medical Knowledge’

More announcements

What's new on this site

Library Home

Library Search

As an advertising man, I can assure you that advertising which does not work does not continue to run. If experience did not show beyond doubt that the great majority of doctors are splendidly responsive to current [prescription drug] advertising, new techniques would be devised in short order. And if, indeed, candor, accuracy, scientific completeness, and a permanent ban on cartoons came to be essential for the successful promotion of [prescription] drugs, advertising would have no choice but to comply.
- Pierre R. Garai (advertising executive) 1963